Francesca Lucibello

446 total citations
8 papers, 114 citations indexed

About

Francesca Lucibello is a scholar working on Oncology, Molecular Biology and Pulmonary and Respiratory Medicine. According to data from OpenAlex, Francesca Lucibello has authored 8 papers receiving a total of 114 indexed citations (citations by other indexed papers that have themselves been cited), including 8 papers in Oncology, 4 papers in Molecular Biology and 4 papers in Pulmonary and Respiratory Medicine. Recurrent topics in Francesca Lucibello's work include Cancer Immunotherapy and Biomarkers (4 papers), Lung Cancer Treatments and Mutations (3 papers) and CRISPR and Genetic Engineering (2 papers). Francesca Lucibello is often cited by papers focused on Cancer Immunotherapy and Biomarkers (4 papers), Lung Cancer Treatments and Mutations (3 papers) and CRISPR and Genetic Engineering (2 papers). Francesca Lucibello collaborates with scholars based in France, United States and Belgium. Francesca Lucibello's co-authors include Arnaud Bayle, Marc Deloger, Sebastián Amigorena, Michael Saitakis, Pierre Loulergue, Aurélie Darbois, Olivier Lantz, Silvia Menegatti, Pierre Gestraud and Ali N. Chamseddine and has published in prestigious journals such as Nucleic Acids Research, Methods in enzymology on CD-ROM/Methods in enzymology and Annals of Oncology.

In The Last Decade

Francesca Lucibello

7 papers receiving 114 citations

Peers

Francesca Lucibello

ONCOL

MB

IMMUN

PRM

ID

Mona Purcell United States

Noor A. M. Bakker Netherlands

Drew Frase United States

Christopher Chang United States

Hélène Ruffieux United Kingdom

Xiangbo Huang China

J. Medioni France

Andreas Obers Australia

Takamasa Ishino Japan

Julia Han Noll Germany

Mona Purcell United States

Francesca Lucibello

42 ×0.5

ONCOL

32 ×0.7

MB

24 ×0.8

IMMUN

12 ×0.9

PRM

9 ×0.8

ID

Citations per year, relative to Francesca Lucibello Francesca Lucibello (= 1×) peers Mona Purcell

Countries citing papers authored by Francesca Lucibello

Since Specialization

Citations

This map shows the geographic impact of Francesca Lucibello's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Francesca Lucibello with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Francesca Lucibello more than expected).

Fields of papers citing papers by Francesca Lucibello

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Francesca Lucibello. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Francesca Lucibello. The network helps show where Francesca Lucibello may publish in the future.

Co-authorship network of co-authors of Francesca Lucibello

This figure shows the co-authorship network connecting the top 25 collaborators of Francesca Lucibello. A scholar is included among the top collaborators of Francesca Lucibello based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Francesca Lucibello. Francesca Lucibello is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

8 of 8 papers shown

1.

Thomas, Quentin, B. Godbert, Virginie Avrillon, et al.. (2025). 208P: Pathological response after neoadjuvant chemotherapy (chemo) and nivolumab (NIVO) in resectable non-small cell lung cancer (NSCLC): Initial results from a French multicenter real-world (rw) retrospective study. Journal of Thoracic Oncology. 20(3). S137–S138.

2.

Huet, C., Clémence Basse, Pieter Bonte, et al.. (2024). Outcomes Analysis of Patients Receiving Local Ablative Therapy for Oligoprogressive Metastatic NSCLC Under First-Line Immunotherapy. Clinical Lung Cancer. 25(8). e402–e410.e3. 1 indexed citations

3.

Menegatti, Silvia, Francesca Lucibello, Julie Helft, et al.. (2021). In vivo genome-wide CRISPR screens identify SOCS1 as intrinsic checkpoint of CD4 ⁺ T _H 1 cell response. Science Immunology. 6(66). eabe8219–eabe8219. 41 indexed citations

4.

Bayle, Arnaud, Mohamed Khettab, Francesca Lucibello, et al.. (2020). Immunogenicity and safety of influenza vaccination in cancer patients receiving checkpoint inhibitors targeting PD-1 or PD-L1. Annals of Oncology. 31(7). 959–961. 26 indexed citations

5.

Dômont, Julien, Ali N. Chamseddine, Sarah Dumont, et al.. (2020). Efficacy and safety of oral metronomic etoposide in adult patients with metastatic osteosarcoma. Cancer Medicine. 10(1). 230–236. 11 indexed citations

6.

Lucibello, Francesca, Silvia Menegatti, & Laurie Menger. (2019). Methods to edit T cells for cancer immunotherapy. Methods in enzymology on CD-ROM/Methods in enzymology. 631. 107–135. 2 indexed citations

7.

Costantini, Adrien, Francesca Lucibello, Jorge Moisés, et al.. (2018). Immunotherapy: a new standard of care in thoracic malignancies?. European Respiratory Journal. 51(2). 1702072–1702072. 11 indexed citations

8.

Lucibello, Francesca. (1997). The differential binding of E2F and CDF repressor complexes contributes to the timing of cell cycle-regulated transcription. Nucleic Acids Research. 25(24). 4921–4925. 22 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact